Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast ButtonSwitch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Stay Informed: Medical and Research Updates
Connect With Us!
 

 

Study Confirms That Rare Mutations Increase Risk of Late-Onset Alzheimer's Disease

September 25, 2013
Source: Neuron

DNA Molecule. New study provides evidence that the ADAM10 gene is a potential therapeutic target for treatment of the late-onset form of Alzheimer's disease.BrightFocus grantee, Jaehong Suh, Ph.D., of Massachusetts General Hospital and Harvard, is the lead author of this paper and has documented in animal models new disease-causing mutations for Alzheimer’s. These results provide evidence that the ADAM10 gene is a potential therapeutic target for treatment of the late-onset form of this brain disease.

Dr. Se Hoon Choi is a co-author of this paper and a current BrightFocus grantee.

Dr. Rudolph Tanzi, senior author of this paper and previous BrightFocus grantee, was the mentor for Dr. Suh’s BrightFocus research grant that ended in 2012, and is the mentor for Dr. Choi.

Massachusetts General Hospital (MGH) researchers have identified and validated two rare gene mutations that appear to cause the common form of Alzheimer's disease (AD) that strikes after the age of 60. The two mutations occur in coding for an enzyme involved in processing the amyloid precursor protein, which now becomes the second pathologically-confirmed gene for late-onset AD and the fifth AD gene overall.

In their report, which will appear in the October 16 issue of Neuron and has been released online, the investigators from the MassGeneral Institute for Neurodegenerative disease (MGH-MIND) describe how the two mutations in ADAM10 increase generation and accumulation of the toxic amyloid beta (A-beta) protein in the brains of a mouse model of AD. The mutations also reduce generation of new neural cells in hippocampus, a part of the brain essential to learning and memory.

"This is the first report to document, in animal models, new pathogenic gene mutations for AD since the reports of the original four genes in the 1990s," says Rudolph Tanzi, PhD, director of the Genetics and Aging Unit at MGH-MIND and senior author of the Neuron paper. "What we found regarding the many effects of these two rare mutations in ADAM10 strongly suggests that diminished activity of this enzyme can cause AD, and these findings support ADAM10 as a promising therapeutic target for both treatment and prevention."

The process leading to the generation of A-beta—which accumulates in characteristic plaques in the brains of AD patients—begins when the amyloid precursor protein (APP) is cut into smaller proteins by enzymes called secretases. A-beta results if APP is first cut into two segments by an enzyme called beta-secretase, and one of those segments is further cut by a gamma-secretase enzyme to release the toxic A-beta fragment. However, processing of APP by an alpha-secretase enzyme-one of which is ADAM10—cuts right through the A-beta region in APP. So instead of generating the toxic A-beta fragment, cleavage with alpha-secretase produces a protein fragment that has been reported to protect and stimulate the generation of neurons in brain.

An earlier study by Tanzi's team reported finding that either of two mutations in ADAM10 increased the risk of AD in seven families with the late-onset form of the disease. Since ADAM10 was already known to be important to alpha-secretase processing of APP, along with having a role in early brain development, the researchers set out to investigate how the observed mutations might lead to the pattern of neurodegeneration characteristic of AD.

Experiments using several strains of transgenic mice—including lines that express both one of the ADAM10 mutations and an APP mutation that leads to AD-like pathology—revealed the following:

  • AD-associated mutations in ADAM10 reduced the release from neurons in the animals' brains of the beneficial protein produced by alpha-secretase processing of APP,
  • Reduced ADAM10 activity caused by the mutations increased the generation of A-beta and its accumulation in plaques, along with producing other AD-associated neurodegenerative signs,
  • Reduced ADAM10 activity also impaired the generation of new neurons in the hippocampus, one of the areas of the brain most vulnerable to neurodegeneration in AD,
  • The AD-associated mutations produce these effects by impairing the correct folding of ADAM10 and interfering with its normal functions.

Jaehong Suh, PhD, of the MGH-MIND Genetics and Aging Research Unit, lead author of the Neuron article, says, "Our current study shows that reducing ADAM10 activity by these AD-associated mutations delivers a 'one-two punch' to the brain-one, decreasing neuroprotective alpha-secretase cleavage products and two, increasing neurotoxic A-beta protein accumulation. Thus, we believe that increasing ADAM10 activity might help to alleviate both genetic and environmental AD risk factors that increase the toxic beta-secretase processing of APP. We're planning to develop optimal ways to increase ADAM10 activity in brain and to further investigate the molecular structure and regulatory mechanism of the ADAM10 enzyme." Suh is an instructor in Neurology, and Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School.

Adapted from Massachusetts General Hospital

View all news updates for Alzheimer's disease


Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.

Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.

::

]]

Shop for a Cause YouTube Twitter Connect With Us Pinterest Google+